Category Archives: Cardiology

E-cigarette use linked to increased risk of heart failure, large study finds – News-Medical.Net

People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure. The findings are being presented at the American College of Cardiology's Annual Scientific Session.

Heart failure is a condition affecting more than 6 million U.S. adults in which the heart becomes too stiff or too weak to pump blood as effectively as it should. It can often lead to debilitating symptoms and frequent hospitalizations as people age. Electronic nicotine products, which include e-cigarettes, vape pens, hookah pens, personal vaporizers and mods, e-cigars, e-pipes and e-hookahs, deliver nicotine in aerosol form without combustion. Since they were first introduced in the U.S. in the late 2000s, electronic nicotine products have often been portrayed as a safer alternative to smoking, but a growing body of research has led to increased concern about potential negative health effects.

More and more studies are linking e-cigarettes to harmful effects and finding that it might not be as safe as previously thought. The difference we saw was substantial. It's worth considering the consequences to your health, especially with regard to heart health."

Yakubu Bene-Alhasan, MD, a resident physician at MedStar Health in Baltimore and the study's lead author

For the study, researchers used data from surveys and electronic health records in All of Us, a large national study of U.S. adults run by the National Institutes of Health, to analyze associations between e-cigarette use and new diagnoses of heart failure in 175,667 study participants (an average age of 52 years and 60.5% female). Of this sample, 3,242 participants developed heart failure within a median follow-up time of 45 months.

The results showed that people who used e-cigarettes at any point were 19% more likely to develop heart failure compared with people who had never used e-cigarettes. In calculating this difference, researchers accounted for a variety of demographic and socioeconomic factors, other heart disease risk factors and participants' past and current use of other substances, including alcohol and tobacco products. The researchers also found no evidence that participants' age, sex or smoking status modified the relationship between e-cigarettes and heart failure.

Breaking the data down by type of heart failure, the increased risk associated with e-cigarette use was statistically significant for heart failure with preserved ejection fraction (HFpEF)-;in which the heart muscle becomes stiff and does not properly fill with blood between contractions. However, this association was not significant for heart failure with reduced ejection fraction (HFrEF)-;in which the heart muscle becomes weak and the left ventricle does not squeeze as hard as it should during contractions. Rates of HFpEF have risen in recent decades, which has led to an increased focus on determining risk factors and improving treatment options for this type of heart failure.

The findings align with previous studies conducted in animals, which signaled e-cigarette use can affect the heart in ways that are relevant to the heart changes involved in heart failure. Other studies in humans have also shown links between e-cigarette use and some risk factors associated with developing heart failure. However, previous studies attempting to assess the direct connection between e-cigarette use and heart failure have been inconclusive, which Bene-Alhasan said is due to the inherent limitations of the cross-sectional study designs, smaller sample sizes and the smaller number of heart failure events seen in previous research.

Researchers said the new study findings point to a need for additional investigations of the potential impacts of vaping on heart health, especially considering the prevalence of e-cigarette use among younger people. Surveys indicate that about 5% to 10% of U.S. teens and adults use e-cigarettes. In 2018, the U.S. Surgeon General called youth e-cigarette use an epidemic and warned about the health risks associated with nicotine addiction.

"I think this research is long overdue, especially considering how much e-cigarettes have gained traction," Bene-Alhasan said. "We don't want to wait too long to find out eventually that it might be harmful, and by that time a lot of harm might already have been done. With more research, we will get to uncover a lot more about the potential health consequences and improve the information out to the public."

Bene-Alhasan also said e-cigarettes are not recommended as a tool to quit smoking, since many people may continue vaping long after they quit smoking. The U.S. Centers for Disease Control and Prevention recommends a combination of counseling and medications as the best strategy for quitting smoking.

Researchers said that the study's prospective observational design allows them to infer, but not conclusively determine, a causal relationship between e-cigarette use and heart failure. However, with its large sample size and detailed data on substance use and health information, Bene-Alhasan said the study is one of the most comprehensive studies to assess this relationship to date.

More here:

E-cigarette use linked to increased risk of heart failure, large study finds - News-Medical.Net

Osso VR and ACC to Develop Cardiac Procedure Training with VR – HIT Consultant

What You Should Know:

Osso VR, the leader in immersive procedural training, announces a groundbreaking collaboration with the American College of Cardiology (ACC) to develop a state-of-the-art training curriculum for left atrial appendage occlusion (LAAO) procedures.

The strategic partnership marks a significant leap forward in the field of medical education, leveraging virtual reality (VR) technology to enhance interventional cardiologists training.

The Focus: Left Atrial Appendage Occlusion (LAAO)

The co-developed curriculum focuses on LAAO, a critical procedure that reduces stroke risk in patients with atrial fibrillation. Mastering LAAO requires a diverse skillset, including Transesophageal Echocardiography (TEE). Osso VRs immersive platform addresses this by providing:

ACCs goal is to improve access to high-quality cardiovascular care. We are thrilled to collaborate with Osso VR to augment traditional interventional training for some of the more complex and cutting-edge procedures in our field, said Ami Bhatt, MD, FACC, ACC Chief Innovation Officer. This collaboration is the first step in a broader effort to increase access to consistent interventional cardiovascular care in the U.S. and globally.

Read more:

Osso VR and ACC to Develop Cardiac Procedure Training with VR - HIT Consultant

Kapil Yadav, M.D., Joins UAMS to Lead Nuclear Cardiology and Vascular Medicine Program – UAMS News

View Larger Image Kapil Yadav, M.D.

March 18, 2024 | LITTLE ROCK Kapil Yadav, M.D., an established interventional cardiologist in central Arkansas, has joined the University of Arkansas for Medical Sciences (UAMS) to lead its Nuclear Cardiology and Vascular Medicine Program.

An associate professor in the Division of Cardiovascular Medicine in the UAMS College of Medicines Department of Internal Medicine, Yadav will treat patients at the UAMS Neighborhood Clinic in Maumelle and at the Outpatient Center on the UAMS campus.

I am delighted that Dr. Kapil Yadav has chosen to move his practice to UAMS, said Paul Mounsey, M.D., Ph.D., director of the UAMS Division of Cardiovascular Medicine.A prominent local cardiologist with wide clinical interests, Dr. Yadav will strengthen both our noninvasive cardiology services, particularly nuclear cardiology, and our interventional cardiology group.

Mounsey added, His interest in peripheral vascular disease will add a new dimension to the cardiovascular disease management at UAMS. He will also have an important role in educating our fellows and residents about cardiology.

Yadav, an interventional and endovascular cardiologist, completed a fellowship in interventional and structural cardiology at the University of Arizona College of Medicine in Tucson in 2018 and a fellowship in cardiovascular disease at Tulane University School of Medicine in New Orleans in 2017.

He completed a residency in internal medicine at Cook County Hospital in Chicago in 2014, after receiving his medical degree from SMS Medical College in India with rotations at Mount Sinai School of Medicine in New York City.

UAMS has an outstanding cardiovascular team, and we are growing the program to provide a wide variety of specialized care, Yadav said.

He is certified by the American Board of Internal Medicine in cardiovascular disease and interventional cardiology, the National Board of Echocardiography and the Board of Nuclear Cardiology.

To schedule an appointment with Yadav, call 501-686-8000 and request the location that works best for you. He will be at the Maumelle clinic on Fridays.

###

More here:

Kapil Yadav, M.D., Joins UAMS to Lead Nuclear Cardiology and Vascular Medicine Program - UAMS News

Doctors form new coalition focused on reducing private equity’s role in cardiology, other healthcare specialties – Cardiovascular Business

Thousands of U.S. physicians have joined forces to launch the Coalition for Patient-Centered Care (CPCC), a new organization focused on reducing the involvement and influence of private equity in the American healthcare system.

CPCCs members include more than 5,000 physicians from 46 U.S. states. The OrthoForum, a Tennessee-based group of private orthopedic practices, the Association for Independent Medicine (AIM) and PELTO are also listed as founding members on the organizations website.

According to the newly formed group, it wants to eliminate tax breaks associated with private equity-funded acquisitions and close loopholes that allow private equity-backed groups to circumvent the ban on the corporate practice of medicine. The group also aims to ensure private equity-funded acquisitions of physician practices are regulated just as closely as any other healthcare merger or acquisition.

Independent physicians across specialties including radiology, anesthesiology, cardiology and more will have a better chance of influencing policy in the right direction than any one specialty standing alone, AIM President Marco Fernandez, MD, a veteran cardiac anesthesiologist and CPCC founding member, told Cardiovascular Business.

When private equity takes over, they often hire less-expensive, less-experienced providers and make them work harder, added surgeon Stephen McCollam, MD, another founding CPCC member. From what Ive seen, this results in lower quality care, higher utilization rates of expensive specialty testing due to a lack of experience and lack of confidence in their clinical abilitiesand higher burnout rates. Ultimately, these effects of private equity ownership cost the patient more while providing lower quality care.

Read more from the original source:

Doctors form new coalition focused on reducing private equity's role in cardiology, other healthcare specialties - Cardiovascular Business

Beth Israel Deaconess Medical Center cardiologist to be honored by American Heart Association – American Heart Association

BOSTON The American Heart Association will present the 2024 Paul Dudley White Award to Dr. Robert E. Gerszten in recognition of his contributions to the field of cardiovascular medicine and outstanding record of mentoring the next generation of researchers, educators and health care professionals.

Dr. Gerszten is chief of the Division of Cardiovascular Medicine at Beth Israel Deaconess Medical Center and the Herman Dana Professor of Medicine at Harvard Medical School. He will receive the award at the Boston Heart and Stroke Ball on May 4.

The Paul Dudley White Award has been presented annually since 1974 to a Boston-based medical professional who has made extraordinary contributions to cardiovascular or stroke care. It is named after one of the citys most revered cardiologists, Dr. Paul Dudley White, a founder of the American Heart Association who is regarded as the father of preventive cardiology.

Dr. Gerszten was selected to receive this years award by a committee of area physicians. In choosing Dr. Gerszten, the committee praised him for his work around predicting, preventing, and treating patients with cardiovascular disease. They also credited his more than 30 years as a volunteer for the American Heart Association and his extensive record of mentorship.

Several colleagues nominated Dr. Gerszten for the award. Among them was Dr. Robert W. Yeh, a cardiologist at Beth Israel Deaconess Medical Center and the Smith Family Professor of Medicine at Harvard Medical School. In his nominating letter, Dr. Yeh commended Dr. Gerszten for dedicating his life to preventing and treating cardiovascular disease.

He has done this through his groundbreaking research, through the mentorship of multiple generations of physician scientists, through a consistent presence at the bedside caring for critically ill patients, and through his leadership of one of the countrys premier cardiovascular divisions, said Dr. Yeh. He has carried out his lifes work with honesty, integrity, professionalism, grace, good humor and relentless determination.

Dr. Gersztens contributions to the scientific community are extensive. He has played a significant role in our understanding of how metabolic issues impact cardiac health. His research has consistently been published in top scientific journals, and his laboratory has continually been funded by prestigious organizations including the National Institutes of Health.

Dr. Gerszten has also served in various volunteer roles for the American Heart Association throughout his career. This includes participating in working groups, grant review activities, and the coordination of community-based fundraising through the Beth Israel Deaconess Medical Center Boston Heart Walk team. Additionally, he has played a pivotal role in planning Scientific Sessions, an annual American Heart Association conference dedicated to highlighting the latest breakthroughs in cardiovascular research.

Dr. Gerszten is also known for being an exceptional mentor, showing an unwavering commitment to training the next generation of leaders in cardiovascular science. Colleagues credit him for fostering a collaborative work environment and for being an exemplary role model.

Over the past year of working daily with Dr. Gerszten in a leadership capacity, I have found him to represent every single humanistic quality that I might imagine distinguished Paul Dudley White, said Dr. Jennifer E. Ho, a cardiologist at Beth Israel Deaconess Medical Center and associate professor of medicine at Harvard Medical School. He cares deeply about the people around him, whether they be colleagues, trainees or patients.

Dr. Gerszten received his bachelors degree from the University of Virginia and his medical degree from Johns Hopkins University. He completed his residency at the University of Pennsylvania and his clinical fellowship in cardiology at Massachusetts General Hospital.

He lives in Brookline with his wife Elena. He is happiest while fishing off Marthas Vineyard, or even while losing to his two sons in tennis. His career has been deeply impacted by his parents, both of whom dedicated their lives to academic medicine as a physician educator and as a social worker.

The Boston Heart and Stroke Ball is a celebration of the year-round Heart of Boston campaign, which supports the American Heart Associations 2024 Health Equity Impact Goal to reduce barriers to health care access and quality. It will be held on Saturday, May 4, at the Omni Boston Hotel at the Seaport.

Dr. Gersztens commitment to the mission of the American Heart Association has been instrumental in our efforts to ensure that every person has the opportunity to live a full, healthy life, said Eric Green, chair of the Heart of Boston campaign and senior vice president and head of development programs at Alnylam Pharmaceuticals. We look forward to honoring his contributions to cardiology and health when we gather at the Heart and Stroke Ball in May.

For more information about the Heart and Stroke Ball, visit heart.org/BostonHB or contact Rachel Adjemian, associate vice president of development, at rachel.adjemian@heart.org.

###

About the American Heart Association

The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the publics health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us onheart.org,Facebook,Xor by calling 1-800-AHA-USA1.

For Media Inquiries:

Chris Camire, Marketing Communications Director

chris.camire@heart.org

For Public Inquiries:

1-800-AHA-USA1 (242-8721)

heart.org and stroke.org

See more here:

Beth Israel Deaconess Medical Center cardiologist to be honored by American Heart Association - American Heart Association

March 19 Doctors on Call Will Focus on Cardiology – KRSL

Local

Written By: Press Release Posted by David Elliott Published Date: 03-18-2024

Doctors on Call, a local production of Smoky Hills PBS, will feature Dr. David Battin with the Heart Center at Salina Regional Health Center on Tuesday, March 19 at 7 PM and will focus on cardiology.

Doctors on Call is a program that provides medical information on a variety of different topics. Medical professionals from throughout the state travel to Bunker Hill to provide information and answer questions from the viewing audience. The doctors presenting each week have expertise in the topic chosen for that program. Questions can be called in during the show or emailed prior to the broadcast.

The program airs live on Smoky Hills PBS at 7 PM on Tuesdays. You can also stream each episode live on the Smoky Hills PBS YouTube channel at http://bit.ly/StreamSmokyHillsPBS.

A schedule of programs and past episodes are available at http://www.SmokyHillsPBS.org.

To submit questions electronically on a specific topic, viewers can send an email to doctors@shptv.org. Questions submitted through email must be received by Noon on the day of the show. During the program, viewers can call 1-800-337-4788.

(Information courtesy SHPBS.)

Originally posted here:

March 19 Doctors on Call Will Focus on Cardiology - KRSL

Cardiologist shares his long journey from Libya to United States – Cardiovascular Business

Almanfi found himself starting from scratch upon arrival in the United States. The U.S. medical system is notoriously rigorous and closed, requiring foreign-trained physicians to undergo a comprehensive evaluation and certification process. This involved passing standardized exams such as the USMLE (United States Medical Licensing Examination) steps, followed by applying for residency through the National Resident Matching Program (NRMP).

For Almanfi, this journey encompassed nearly a decade of dedicated effort, including three years of internal medicine residency and additional training in cardiology and interventional cardiology. The process demanded resilience and persistence, as foreign-trained physicians often encounter bureaucratic roadblocks and lengthy timelines in obtaining licensure and certification to practice medicine in the U.S. The requirement to meet the U.S certifications can be a significant deterrent for individuals who have already established careers in their home countries or seek expedited pathways to practice medicine in the U.S.

"I think if someone has a goal in mind and has determination to do this, maybe they can go through the process. I know it's painful, it can be long, but it can get you to your dream and get you to have a job and have a living and even become a U.S. citizen. That's probably the longest way and probably the official way," Almanfi said.

Almanfi suggests exploring alternative avenues for skill development, such as attending conferences, participating in hands-on training programs and leveraging online resources and simulators to enhance clinical proficiency.

Almanfi's own experiences underscore the significance of networking and utilizing social media platforms as valuable tools for professional advancement. As a social media ambassador for prestigious medical conferences, he has leveraged digital platforms to connect with colleagues worldwide, share insights, and collaborate on educational initiatives. Social media serves as a gateway for international physicians to engage with the global medical community, facilitating knowledge exchange, networking opportunities, and professional development.

"I think social media has became a central part of almost everything in our life nowadays. Not only in politics but also in medicine. I have been doing this for 10 years, which I think has impacted my career. And so I became more involved with physicians not only within the United States, but also outside the United States. Social media, it became like a window for the people there to look at the outside world. And so if you're traveling to the United States, you could see everything through social media, especially if you are connected with people or organizations that have a presence on social media," Almanfi explained.

Read the original post:

Cardiologist shares his long journey from Libya to United States - Cardiovascular Business

Cardiologists share historic research that led to FDA’s long-awaited approval of coronary DCB – Cardiovascular Business

Overall, clinical procedural success rates (92.1% for DCB patients vs. 88.7% for uncoated balloon patients) and technical success rates (93.4% for DCB patients vs. 89.7% for uncoated balloon patients) were similar. Bailout stents, meanwhile, were required for three patients treated with a paclitaxel-coated balloon and one patient treated with an uncoated balloon.

Target lesion failure after 12 months was seen in 17.9% of DCB patients and 28.6% of uncoated balloon patients. This difference was primarily attributed to lower rates of ischemia-driven revascularization and target vessel myocardial infarction among patients in the DCB group.

Drug-coated balloons have emerged internationally as an alternative treatment option, but despite promising international data, they have not been previously evaluated or approved for use in the United States, lead investigator Robert W. Yeh, MD, MSc, MBA, director of the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology and section chief of interventional cardiology at Beth Israel Deaconess Medical Center, said in a statement. Even with advances in stent technology, patients with coronary in-stent restenosis continue to comprise approximately 10% of individuals undergoing angioplasty interventions each year. In particular, patients with multiple prior stents have very poor long-term outcomes. There's growing sentiment that drug-coated balloons could address an unmet clinical need among patients with coronary artery disease in the United States.

Click here to read the full analysis in JAMA, a journal from the American Medical Association.

When the initial positive results from AGENT IDE were presented at TCT 2023, cardiologists were thrilled that a coronary DCB could finally be on its way toward FDA approval.

Our European colleagues have had these devices for a decade, Ajay J. Kirtane, MD, an interventional cardiologist with the Columbia University Department of Medicine, said during a TCT press conference in October 2023. In the United States, we basically tell patients routinely that we can use a peripheral balloon that is too big for your coronary and try to put it in your coronary to prevent the restenosis from happening, or you can buy a ticket to London and go over there to get this treated. Its embarrassing.

American College of Cardiology President B. Hadley Wilson, MD, meanwhile, described the new analysis as a game changer.

For 25 years, weve been trying to peel back this restenosis problem, he said during the same press conference. Now we can see light at the end of the tunnel.

Boston Scientific said the Agent DCB should be available on the U.S. market in the coming months.

In addition, AGENT IDEs researchers will be tracking patient data for up to five years, so expect updates on their findings as time goes on.

Follow this link:

Cardiologists share historic research that led to FDA's long-awaited approval of coronary DCB - Cardiovascular Business

Most physicians think private equity is bad for healthcare – Cardiovascular Business

Overall, 60.8% of physicians said they view the involvement of PE in healthcare in a negative light. Just 10.5% of physicians said they have a positive opinion about PE, and the remaining 28.8% said they were neutral. In addition, 52% of respondents said they think PE ownership is worse than being owned by a not-for-profit hospital or health system.

What is it about PE involvement that worries physicians the most? Its potential impact on physician well-being, healthcare prices/spending and health equity were the three most common concerns.

The authors also noted that the small subset of physicians who are owned by a PE-backed group were less likely to report high professional satisfaction and autonomy than physicians not owned by a PE-backed group. They were also less likely to say they would likely remain with their employer.

While this survey had a limited sample size and is not generalizable to non-ACP members, our findings add to the dearth of evidence on PEs perceived effects on physicians, the authors wrote. Our estimates of PE-involved physicians mirror those in the literature and suggest new areas for inquiry around clinical practice and workplace experience.

Read the full research letter in JAMA Internal Medicine here.

The rise of PE continues to be one of the biggest trends in all of healthcare, and its presence in cardiologyseems to be growing by the day. Cardiovascular Associates of America, Cardiovascular Logistics and other PE-backed cardiology management groups are acquiring more and more practices, and the trend has shown no signs of slowing down.

Click here and here for additional insights into PE's impact on cardiovascular care in the United States.

Originally posted here:

Most physicians think private equity is bad for healthcare - Cardiovascular Business

Meth-Related Cardiomyopathy: Where the Biggest Clusters Are – Medpage Today

The American West has seen the biggest surge of cardiomyopathy-associated hospital admissions among methamphetamine users, based on 13 years of the latest available hospital admission data.

The National Inpatient Sample (NIS) showed that methamphetamine-related cardiomyopathy admissions spiked by 231% from 2008 to 2020 nationwide -- whereas overall admissions for heart failure increased just 12% during this period, according to Mohammad Bhuiyan, PhD, of Louisiana State University Health Sciences Center at Shreveport, and colleagues.

They reported various geographical and social disparities evident across methamphetamine-related cardiomyopathy admissions:

"Demographically, cardiomyopathy among methamphetamine users occurs predominantly in middle-aged patients and men and tends to be concentrated more in the western region of the United States," Bhuiyan's team reported in JACC: Advances.

Methamphetamine (popularly known as "meth") is a highly addictive psychostimulant drug. It is available as a prescription drug for obesity and attention deficit-hyperactivity disorder, while illegal versions are derived from over-the-counter drugs. An estimated 1.6 million U.S. adults reported past-year methamphetamine use in 2015-2018, the CDC estimates.

Methamphetamine has known links to cardiovascular disease (CVD), including cardiomyopathy, heart failure, pulmonary hypertension, and coronary artery disease.

"Given the rapidly increasing global burden of methamphetamine-associated cardiomyopathy, this work ... should be a call to action for researchers, healthcare providers, and policymakers to fight this growing epidemic. Importantly, the healthcare system must also acknowledge and address its bias towards patients with substance use disorders," urged cardiologist Nisha Parikh, MD, MPH, of University of California San Francisco Health, and two colleagues.

In an accompanying editorial, the trio said the present NIS study extends prior work showing that meth-associated heart failure (MethHF) hospitalizations increased at an exponential rate between 2002 and 2014, particularly on the West Coast and among men, younger patients, and lower socioeconomic groups. Also disproportionately affected were people of Hispanic, Native American, and Asian/Pacific Islander descent.

"This work should lead us to interrogate why certain geographic areas and populations suffer a disproportionate burden of MethHF and the ways in which local public policies, differential availability of psychostimulant drugs, and socioeconomic disparities have shaped the epidemic," Parikh and colleagues wrote.

They stressed the importance of targeted interventions -- development of a pharmacotherapy for methamphetamine use disorder (MAUD), for example -- and recognition of the "competing health and life priorities relevant for this vulnerable patient population."

"We should also consider employing innovative, multidisciplinary approaches to co-manage heart failure and MAUD. For example, the development of specialty heart failure clinics that also offer contingency management -- a highly effective, evidence-based behavioral treatment for MAUD -- deserves further study and potential scale up," the editorialists wrote.

The NIS study relied on hospital records from all 50 states and captured over 12.8 million cardiomyopathy-associated hospital admissions (59.3% men, over 57% were older than 65) during the study period.

Of these admissions, 222,727 were related to methamphetamine users based on medical records (58.5% men, over 55% were ages 41-64 years). Notably, people who used methamphetamine together with other drugs were excluded from the study.

Bhuiyan's group acknowledged that the study lacked individual-level data and any postdischarge information. The authors were also uncertain how people came to be diagnosed as methamphetamine users.

"Further research is warranted to identify high-risk populations and develop strategies to prevent and mitigate CVD among methamphetamine users," they urged.

Nicole Lou is a reporter for MedPage Today, where she covers cardiology news and other developments in medicine. Follow

Disclosures

The study was supported by grants or awards from the National Institutes of Health and Louisiana State University.

Bhuiyan and Parikh had no disclosures.

Co-editorialists reported support from the NIDA and Chan Zuckerberg BioHub San Francisco.

Primary Source

JACC: Advances

Source Reference: Al-Yafeai Z, et al "Cardiomyopathy-associated hospital admissions among methamphetamine users: geographical and social disparities" JACC Adv 2024; DOI: 10.1016/j.jacadv.2024.100840.

Secondary Source

JACC: Advances

Source Reference: Walker SL, et al "Facing a tsunami: methamphetamine heart failure demands novel approaches" JACC Adv 2024; DOI: 10.1016/j.jacadv.2024.100838.

Read the original here:

Meth-Related Cardiomyopathy: Where the Biggest Clusters Are - Medpage Today